Trial reportIndian journal of ophthalmology2012
Efficacy of preoperative injection versus intraoperative application of mitomycin in recurrent pterygium surgery.
Trial report in Indian journal of ophthalmology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 21 citations in OpenAlex.
- Applications of Mitomycin C in Cornea and External Disease.Turkish journal of ophthalmology · 2023Review
- Evaluating the Efficacy and Safety of Different Pterygium Surgeries: A Review of the Literature.International journal of environmental research and public health · 2022Review
- Efficacy of Subconjunctival Bevacizumab Injections before and after Surgical Excision in Preventing Pterygium Recurrence.Journal of ophthalmology · 2017Article
- Mitomycin C in pterygium treatment.International journal of ophthalmology · 2016Review
- Does topical bevacizumab prevent postoperative recurrence after pterygium surgery with conjunctival autografting?International journal of ophthalmology · 2014Article
- Pre-operative sub-conjunctival mitomycin C 24 hours before excision of recurrent pterygium.Indian journal of ophthalmology · 2013Article
- Pre- and intraoperative mitomycin C for recurrent pterygium associated with symblepharon.Clinical ophthalmology (Auckland, N.Z.) · 2013Article
- Recurrent Pterygium: A Review.Journal of current ophthalmologyReview
- Pterygium: an update on pathophysiology, clinical features, and management.Therapeutic advances in ophthalmologyReview
- Outcomes of preoperative intrapterygial injection of mitomycin C for pterygium excision with and without inferior conjunctival flap.Oman journal of ophthalmologyArticle
Corrections and comments
- Commented on by
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo determine the efficacy of preoperative subconjunctival injection of mitomycin C a day before surgery in the management of recurrent pterygium. MATERIALS AND
methodsRandomized comparative case series. Fifty eyes with recurrent pterygium were randomly divided into two groups; the mitomycin injection group (25 eyes) and the mitomycin application group (25 eyes). The mitomycin injection group underwent preoperative subconjunctival injection of mitomycin C in low dose (0.1 ml of 0.15 mg/ml) a day before bare sclera pterygium excision surgery. The mitomycin application group underwent bare sclera pterygium excision with topical application of mitomycin C (same concentration).
resultsAt one year of follow-up, 24 of 25 eyes (96%) in the mitomycin injection group and 23 of 25 (92%) eyes in the mitomycin application group were free of recurrence. The difference was statistically insignificant. As regards postoperative complications, delayed epithelization (more than two weeks) occurred in two eyes (8%) in the mitomycin injection group and in one eye (4%) in the mitomycin application group. Scleral thinning was reported in one eye (4%) in the mitomycin application group which resolved within three weeks after surgery, no other serious postoperative complications were reported.
conclusionPreoperative subconjunctival injection of mitomycin C in low dose (0.1 ml of 0.15 mg/ml) a day before pterygium surgery is a simple and effective modality for management of recurrent pterygium. It has the advantage of low recurrence and complications' rate.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.